AIHTA - Publications - Search - [Avastin® (Bevacizumab): Off-label use in cancer therapy]

Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: p. 2.

[thumbnail of HTA-Newsletter 58]
PDF (HTA-Newsletter 58) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Official URL:

Item Type:HTA Newsletter Item
Keywords:Avastin (bevacizumab), angiogenesis inhibitor, vascular endothelial growth factor (VEGF), off-label use, cancer therapy, non-small cell lung cancer (NSCLC), renal cell carcinoma, non-colorectal cancer, adverse effects, risks, approval
Subjects:QW Microbiology. Immunology
WF Respiratory system
WJ Urogenital system > WJ 300-378 Kidney
Related URLs:
References:1. BCBS/USA 2006: Off-Label Uses of Bevacizumab: Breast and Lung Cancer Indications. URL:

2. BCBS/USA 2006: Off-Label Uses of Bevacizumab: Renal Cell Carcinoma and Other Miscellaneous Non-Colorectal Cancer Indications. URL:

3. Zhu X et al. 2007: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49: 186-93.
Deposited on:18 Jan 2008 17:57
Last Modified:15 Jul 2020 17:21

Repository Staff Only: item control page